YiChang HEC ChangJiang Pharmaceutical Co., Ltd. More Details
Trading at 73% below our estimate of its fair value
Earnings are forecast to grow 5.05% per year
Earnings grew by 22.5% over the past year
High level of non-cash earnings
Has a high level of debt
Unstable dividend track record
Undervalued with adequate balance sheet.
Search for a company to compare.